A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

Summary

The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity

Timeline

Start

2023-04-05

Primary completion

2024-06-20

Completion

2024-10-10

Outcome

Met primary endpoint

paper the respective estimated treatment differences compared with placebo were -9·2% (97% CI -11·0 to -7·5) PMID 40555243 ↗

paper the respective estimated treatment differences versus placebo were 60% (98% CI 50 to 71), 68% (58 to 78), and 70% (61 to 80; all p<0·0001). PMID 40555243 ↗

Publications

• Ji L, Gao L, Xue H, Tian J, Wang K, Jiang H, Huang C, Lian Q, Yuan M, Gao G, Lu Y, Han J, Fu W, Wang H, Zhang Y, Shi X, Wen B, Shi B, Hu W, Guo T, Xing Y, Li Y, Li Q, Zheng Q, Yang M, Ning J, Guo M, Li Y, Pan H. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025 Sep;13(9):777-789. doi: 10.1016/S2213-8587(25)00141-X. Epub 2025 Jun 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ecnoglutide	Protein / enzyme biologic	1.2 mg	Subcutaneous
Subject	Ecnoglutide	Protein / enzyme biologic	1.8 mg	Subcutaneous
Subject	Ecnoglutide	Protein / enzyme biologic	2.4 mg	Subcutaneous

Indications

No indication recorded.